New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease | Biogen – Biogen

1. New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease | Biogen Biogen
2. More convenient form of breakthrough Alzheimer’s drug Leqembi shows promising results in study CNBC
3. Biogen’s Alzheimer’s drug slows cognitive decline in early study STAT
4. Biogen, Eli Lilly present new clinical data in race to field Alzheimer’s treatments The Boston Globe
5. Alzheimer’s drug Leqembi could be given as shots rather than IV infusion, study suggests CNN
6. View Full Coverage on Google News

Read original article here